 |
|
|
|||||
Investors are shifting focus from technology stocks to industrial, healthcare, and small-cap companies. This move signals a potential broadening of market leadership. Fourth-quarter earnings reports will be crucial in determining the sustainability of this trend. Experts believe conditions are favorable for this expansion, with AI benefits expected to reach various sectors.
Category:
News and Media
Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy's face softer US sales. Divi's Laboratories expects strong custom synthesis growth.
Category:
News and Media
Mutual fund managers adjusted portfolios in December, buying Swiggy and Zomato amid underperformance and favoring Tata Consultancy Services over Infosys. They also rotated allocations in InterGlobe Aviation following a selloff due to mass flight cancellations, preparing for the Q3 results season.
Category:
News and Media
All news |
||||||||||||||||||
|
||||||||||||||||||